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Introduction: Since 1991, three sequential prospective
multi-national clinical trials (including 39 participating in-
stitutions) have been conducted by the “Head Start” Con-
sortium for young children newly-diagnosed with malignant
brain tumors, designed to improve both the cure rate and
quality of survival of such children through replace-
ment (<6yo) or reduction in dosage of brain irradiation (6-
10yo) by a single cycle of marrow-ablative chemotherapy
with autologous hematopoieic cell rescue as consolidation
following initial induction chemotherapy. We present data
documenting progressively decreasing morbidity and mor-
tality of the marrow-ablative consolidation phase of treat-
ment as well as the improvement in disease-speciﬁc survival.
Methods: Overall treatment design has remained un-
changed throughout the 3 prospective trials; 5 cycles of in-
duction chemotherapy (vincristine, cisplatin, etoposide,
cyclophosphamide with/without high-dose methotrexate
(HD-MTX) over 4 days each 21-28 days cycle (HSI-II) or 3
cycles of the prior regimen + HD-MTX alternating with 2
cycles of vincristine, oral etoposide, temozolomide and
cyclophosphamide) were followed efor patients with mini-
mal residual, non-progressive tumor - by a single marrow-
ablative cycle consisting of thiotepa (300mg/M2/day x 3
days), etoposide (250mg/M2/day x 3 days) on days -5 to -3,
preceded by carboplatin (500mg/M2/day or AUC of 6/day by
Calvert formula, whichever was the lower of the methods of
dosing) on days -8 to -6. Bone Marrow (HSI) or leukapher-
esed peripheral blood hematopoietic cells under Neupogen
stimulation (HSII-III) were obtained following recovery
from the ﬁrst and/or second induction cycles. Radiotherapy
was reserved for patients with residual tumor following
completion of induction or >6yo.
Results: A total of 216 children were enrolled on 3 consec-
utive HS trials with medulloblastoma, other primitive neuro-
ectodermal tumors, ependymoma, atypical teratoid/rhab-
doid tumors, malignant glial tumors and other malignant
CNS tumors and underwent marrow-ablative chemotherapy,
the 100 day toxic mortality for whom steadily declined from
HSI (3/37¼8.1%; 1 day +4 hepato-renal failure; 1 day +26 viral
pneumonitis post-multi-organ system failure; 1 day +21
post-respiratory arrest due to oropharyngeal mucositis)
through HSII (1/46¼2.2%; pseudomonas aerugenosa sepsis)
to HSIII (1/131 ¼ 0.8%; VOD day +21). Data on time to
engraftment, transplant-related morbidities and long-term
disease-speciﬁc survival will also be presented.
Conclusions: Increasing experience with the marrow-abla-
tive chemotherapy regimen, combined with improved leu-
kapheresis and post-reinfusion supportive care techniques,
have likely contributed to the steady decline in transplant-
related mortality in this patient population and contributed
towards improved overall survival.88
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Background: TBI-based preparative regimen has been
widely recommended for pediatric ALL. These assumptions
are based on older registry studies. Because of the signiﬁ-
cantly high rates of serious late effect using TBI in pediatric
patients it is of utmost importance to ﬁnd alternative regi-
mens. Chemotherapy regimens are developed to minimize
the toxicities of irradiation-based regimens.
Methods: Since the year 1994, 111 pediatric patients (78
male &33 female: 72 in CR and 39 not in CR) with ALL un-
derwent HSCT in our center using a TBI-free conditioning.
Here, we describe the outcomes of HSCT of the 72 patients in
CR: 30 patients were in ﬁrst CR, 28 second CR, and 14 third
CR. Only very high-risk patients underwent HSCT in the ﬁrst
CR. Patients were treated and classiﬁed according to BFM
protocols. The conditioning regimen was included of
Busulfan (IV or Oral) and Cyclophosphamide with or without
ATG. For GVHD prophylaxis, patients received cyclosporine
with or without methotrexate.
Outcomes: Patients underwent transplantation from sib-
ling donors (n¼58), other related donors (n¼10), unre-
lated donor (n¼4). Source of grafts were peripheral blood
(n¼60), bone marrow (n¼7) and cord blood (n¼5). The
probability of neutrophil engraftment (at day60) was 94+-
3% (med.time to of 14days) and of platelets-engraftment
was 90+-10% (med.time 22days). The estimated 5-year
leukemic free survival (LFS) was 73%+-6% (82+-7% in CR1,
71+-10% in CR2 and 38+-25% in CR>¼2). Relapse rates
were 8+-5% in CR1, 22+-9% in CR2 and 20+-17% in CR>¼2.
Acute GvHD grade 2-4 occurred in 49+-5% patients and
15+-5% patients have experienced chronic extended
GvHD.
Conclusion: A TBI-free (Bu/Cy) preparative regimens can be
used in pediatric ALL with encouraging LFS rates, similar to
what is reported in literature using TBI. Well-designed ran-
domized trials are needed to better clarify the difference
between radiation and TBI-free conditioning regimens in
pediatric ALL, including late effects.
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In 2009, we initiated a prospective study of chimerism-
based preemptive IT consisting of fast withdrawal of
